ATERIS Technologies LLC is dedicated to the advancement of knowledge of the nervous system through discovery, development and eventual sales of diagnostic devices and therapeutics to provide an early warning from exposure to environmental and toxic chemicals. Specifically, the firms focus is on uncovering biomarkers resulting from chemical threats that injure the nervous system. Currently under development is a diagnostic testing system for home use and a monitoring system for clinical use for individuals exposed to potentially harmful amounts of organophosphate insecticides. ATERIS also has expertise in retooling pesticide synthesis processes to develop safer and less toxic pesticides.
Underlying technologies used at ATERIS (combinatorial chemistry, fluorogenic polymers, molecular modeling, synthesis and chemical genetics) enable rapid discovery of new medical products and diagnostic tools that increase throughput and decrease investigative costs. Currently, the firms flagship product, a single use, lateral flow-based device for detection of organophosphate overexposure, is currently in the latter stages of development and is anticipated to be manufactured and commercialized.
